Medical cannabis & the future of cancer treatments
Dr Stephen Barnhill MD, CEO of Apollon Formularies Plc, examines medical cannabis and the future of cancer treatments across the UK and the European healthcare sectors
Dr Stephen Barnhill MD, CEO of Apollon Formularies Plc, examines medical cannabis and the future of cancer treatments across the UK and the European healthcare sectors
Medical cannabis has been gaining traction as a potential treatment for rheumatoid arthritis (RA).
The New Mexico Department of Health (DOH) confirms a stable, long-term supply of medical cannabis is and will continue to be available for patients ahead of statewide recreational cannabis sales beginning later this week.
In Minnesota, medical cannabis was approved for use in 2014.
There is not a single pharmacological agent with demonstrated therapeutic efficacy for traumatic brain injury (TBI).
Access to medical cannabis may reduce opioid prescriptions in patients with osteoarthritis, with opioids no longer required in more than one-third of patients after medical cannabis certification, results presented here show.
Using cannabis to treat symptoms of chronic kidney disease (CKD) may hold promise, but a lack of related knowledge and acceptance among treating doctors may be slowing down progress.
The Kentucky House of Representatives on Thursday passed a bill to legalize medical marijuana in the state. The legislation now heads to the Senate.
In the UK, medical cannabis was approved in November 2018, leading many patients to believe that the medicine would now be available on the NHS.
Purpose of review: The purpose of this study was to provide the most up-to-date scientific evidence of the potential analgesic effects, or lack thereof, of the marijuana plant (cannabis) or cannabinoids, and of safety or tolerability of their long-term use.